Tabi Z, Man S
Department of Oncology and Palliative Medicine, Velindre Hospital, Whitchurch, Cardiff CF14 2TL, UK.
Adv Drug Deliv Rev. 2006 Oct 1;58(8):902-15. doi: 10.1016/j.addr.2006.05.004. Epub 2006 Aug 7.
The first generation of human cancer vaccines has been tested in phase III clinical trials, but only a few of these have demonstrated sufficient efficacy to be licensed for clinical use. This article reviews some of the mechanisms that could contribute to these limited clinical responses, and highlights the challenges faced for development of future vaccines.
第一代人类癌症疫苗已在III期临床试验中进行了测试，但其中只有少数几种显示出足够的疗效，从而获得临床使用许可。本文回顾了一些可能导致这些有限临床反应的机制，并强调了未来疫苗开发所面临的挑战。
